Sarcoma  >>  nintedanib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nintedanib / Generic mfg.
NCT01380782: BIBF 1120 for Recurrent High-Grade Gliomas

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
37
US
BIBF 1120
Patrick Y. Wen, MD, Boehringer Ingelheim, Wake Forest University Health Sciences, University of Virginia, Massachusetts General Hospital, The Cleveland Clinic
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
07/13
07/14
ANITA, NCT02808247 / 2016-002093-12: Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma

Terminated
2
80
Europe
Nintedanib, BIBF1120, Ifosfamide
European Organisation for Research and Treatment of Cancer - EORTC, Boehringer Ingelheim
Sarcoma, Soft Tissue
11/20
04/21

Download Options